Expected benefits from the treatments and monitoring outlined in these CPG include: (i) elimination or reduction of pain episodes; (ii) increased fetal hemoglobin (Hb F) production; (iii) slight increase in total Hb concentration; (iv) reduced acute chest syndrome (ACS) episodes; (v) reduced hospitalizations; (vi) reduced transfusions; (vii) regression or stabilization of organ or tissue damage; (viii) lower infection risk; and (ix) improved well-being, quality of life, and survival rates. The gene discussed is GSTM1; the disease is acute chest syndrome.